Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MicroSectors FANG and Innovation 3X Leveraged ETN vs Johnson & Johnson — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $36.72 (market cap $2.98B), while Johnson & Johnson trades at $261.41 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 207.4× MicroSectors FANG and Innovation 3X Leveraged ETN's market cap, and Johnson & Johnson pays a 2.09% dividend while MicroSectors FANG and Innovation 3X Leveraged ETN pays none. Which is the better fit depends on your goals — on Pluang, investors hold MicroSectors FANG and Innovation 3X Leveraged ETN for 19 Days and Johnson & Johnson for 129 Days on average.
| FNGU | JNJ | |
|---|---|---|
Market Cap | $2.98B | $618.09B |
Volume | 4,682,352 | 6,050,983 |
Sector | Leveraged / Inverse | Health |
52-Week High | $37.20 | $278.43 |
52-Week Low | $13.73 | $186.00 |
Typical Hold Time | 19 Days | 129 Days |
Enterprise Value | — | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNGU, a 3x leveraged ETN tracking major tech stocks, trades at $36.82, down 1.02% today. Technical signals are bullish based on moving averages, with neutral oscillators suggesting potential consolidation. Support and resistance levels are tightly clustered between $33 and $39, indicating a critical price zone. Recent news highlights the ETN's high volatility, having lost 87% during past tech sector downturns, underscoring its leveraged risk profile.
The outlook for FNGU hinges on sustained strength in its underlying tech holdings like Nvidia and Apple. While bullish momentum offers upside potential, the extreme leverage amplifies risks during market corrections. Investors face significant volatility, with losses magnified in downturns, making it suitable only for those with high risk tolerance and short-term horizons.
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
